Modified non-pituitary down regulation protocol for ovulation induction in ART (IVF & ICSI) : Research Article

Elmahaishi MS

doi:10.58372/2835-6276.1127

Authors

Elmahaishi MS

DOI:

https://doi.org/10.58372/2835-6276.1127

Keywords:

Modified non-pituitary , social life

Abstract

Infertility is a unique medical condition because it involves a couple rather than a single individual. Both the prevalence of infertility and the number of patients seeking the treatment of this disorder are increasing. Although it is not a physically debilitating disease; infertility may severely affect the couples psychological, sexual and social life.

From literature we found that agonist protocol has taken long time in treating the patient and not used for polycystic patient because of risk of hyperstimulation while antagonist protocol take less time and less drug cosumed and has advantages in polycystic ovaries patient,. In our study on 241 patients who admitted for ICSI and started their ovarian stimulation by HMG or FSH without pituitary down regulation protocol + single dose orgalutran (GnRH antagonist Ganirelix acetate) we find that pregnancy outcome same as in the other protocols with less side effects, good quality and excellent embryos, with low cost to the patient.

References

Zahmatkeshan M, Naghdi M, Farjam M, et al. ART Registries-Characteristics and experiences: A comparative study. J Family Med Prim Care 2019; 8:44954. [Crossref] [PubMed].

Elmahaishi Asma, Zawawa Alia, Elmahaishi MS. Non-Pituitary Down Regulation Protocol for Ovulation Induction in ART (IVF & ICSI). Gynecol Reprod Health. 2019; 3(4): 1-5.

Crustacean color-change hormone: amino acid sequence and chemical synthesis P. Fernlund, L. Josefsson ; Science, 177 (4044) (1972), pp. 173175.

Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod. 2000; 15: 19651968.

Franco JG, Baruffi RL, Mauri AL, et al. GnRH agonist versus GnRH antagonist in poor ovarian responders: a meta-analysis. Reprod Biomed Online. 2006; 13: 618-627

Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev. 2000; CD001299.

vanLoenen AC, Huirne JA, Schats R, et al. GnRH agonists, antagonists, and assisted conception. Semin Reprod Med. 2002; 20: 349-364.

Grow D, Kawwass JF, Kulkarni AD, et al. GnRH agonist and GnRH antagonist protocols: comparison of outcomes among good-prognosis patients using national surveillance data. Reprod Biomed Online. 2014; 29: 299-304.

Khalaf M, Mittre H, Levallet J, et al. GnRH agonist and GnRH antagonist protocols in ovarian stimulation: differential regulation pathway of aromatase expression in human granulosa cells. Reprod Biomed Online. 2010; 21: 56-65.

Lai Q, Zhang H, Zhu G, et al. Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles. Int J Clin Exp Pathol. 2013; 6: 19031910.

Steptoe PC, Edwards RG, Birth after the reimplantation of a human embryo, Lancet 2:366, 1978.

Aboulghar MA, Mansour RT, Serour GA, Amin YM, Sattar MA, Ramzy AM, In vitro fertilization in a spontaneous cycle: a successfulsimple protocol, J Obstet Gynaecol (Tokyo 1995) 21:337, 1995.

Nargund G, Waterstone J, Bland J, Philips Z, Parsons J, Campbell S, Cumulative conception and live birth rates in natural (unstimulated) IVF cycles, Hum Reprod 16:259, 2001.

Pelinck MJ, Hoek A, Simons AH, Heineman MJ, Efficacy of natural cycle IVF: a review of the literature, Hum Reprod Update 8:129, 2002.

Trounson AO, Leeton JF, Wood C, Webb J, Wood J, Pregnancies in humans by fertilization in vitro and embryo transfer in the controlled ovulatory cycle, Science 212:681, 1981.

Quigley MM, Schmidt CL, Beauchamp PJ, Pace-Owens S, Berkowitz AS, Wolf DP, Enhanced follicular recruitment in an in vitro fertilization program: clomiphene alone versus a clomiphene/human menopausal gonadotropin combination, Fertil Steril 42:25, 1984.

Macklon NS, Stouffer RL, Giudice LC, Fauser BC, The science behind 25 years of ovarian stimulation for in vitro fertilization, Endocr Rev 27:170, 2006.

Weigert M, Krischker U, Pohl M, Poschalko G, Kindermann C, Feichtinger W, Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study, Fertil Steril 78:34, 2002.

Dhont M, Onghena A, Coetsier T, De Sutter P, Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction, Hum Reprod 10:791, 1995.

Meldrum D, GnRH agonists as adjuncts for in vitro fertilization, Obstet Gynecol Surv 44:314, 1989.

Edwards RG, Lobo R, Bouchard P, Time to revolutionize ovarian stimulation, Hum Reprod 11:917, 1996.

Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Bernards JM, RekersMombarg LT, Schoemaker J, Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study, Hum Reprod 15:2333, 2000.

Henne MB, Milki AA, Uterine position at real embryo transfer compared with mock embryo transfer, Hum Reprod 19:570, 2004.

Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology, 2015 Assisted Reproductive Technology National Summary Report, 2017.

Ata B, Seli E, A universal freeze allstrategy: why it is not warranted, Curr Opin Obstet Gynecol 29:136, 2017.

Smitz J, Camus M, Devroey P, Erard P, Wisanto A, Van Steirteghem AC, Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization, Hum Reprod 5:933, 1990.

MacDougall MJ, Tan SL, Jacobs HS, In-vitro fertilization and the ovarian hyperstimulation syndrome, Hum Reprod 7:597, 1992.

Rizk B, Smitz J, Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures, Hum Reprod 7:320, 1992.

Padilla SL, Dugan K, Maruschak V, Shalika S, Smith RD, Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders, Fertil Steril 65:796, 1996.

Garcia JE, Padilla SL, Bayati J, Baramki TA, Follicular phase gonadotropinreleasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization, Fertil Steril 53:302,1990.

Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R, The use of GnRH antagonists in ovarian stimulation, Hum Reprod Update 8:279, 2002.

Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P, Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormonereleasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group, Hum Reprod 15:526, 2000.

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian.

Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P, Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation, Fertil Steril 67:917, 1997.

Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmuller D, Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation, Hum Reprod 9:788, 1994.

Ludwig M, Katalinic A, Banz C, Schroder AK, Loning M, Weiss JM, Diedrich K, Tailoring the GnRH antagonist cetrorelix acetate to individual patients’ needs in ovarian stimulation for IVF: results of a prospective, randomized study, Hum Reprod 17:2842, 2002.

Klipstein S, Reindollar RH, Regan MM, Alper MM, Initiation of the gonadotropin-releasing hormone antagonist ganirelix for in vitro fertilization cycles in which the lead follicle is >14 mm, Fertil Steril 81:714, 2004.

Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P, Frydman R, Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin), Fertil Steril 73:314, 2000.

Olivennes F, Diedrich K, Frydman R, Felberbaum RE, Howles CM; Cerotide Multiple Dose International Study Group; Cetrotide Single Dose International Study Group, Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences, Reprod Biomed Online 6:432, 2003.

Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R, the use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVFembryo transfer: a dose finding study of 3 versus 2 mg, Hum Reprod 13:2411, 1998.

Fanchin R, Cunha-Filho JS, Schonauer LM, Kadoch IJ, Cohen-Bacri P, Frydman R, Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens, Fertil Steril 79:316, 2003.